Updated efficacy and safety analysis of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) for relapsed or refractory multiple myeloma (rrmm; pollux) — Philippe Moreau (2018) | RDL Network
Updated efficacy and safety analysis of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) for relapsed or refractory multiple myeloma (rrmm; pollux)
Meletios A Dimopoulos, Darrell White, Lofti Benboubker, Gordon Cook, Merav Leiba, James Morton, P. Joy Ho, Kihyun Kım, Naoki Takezako, Sonali Trivedi, Kaida Wu, Tineke Casneuf, Christopher Chiu, Jordan M. Schecter, Philippe Moreau
Nizar J. Bahlis, Philippe Moreau, Hareth Nahi, Torben Plesner, Hartmut Goldschmidt, Kenshi Suzuki, Robert Z. Orlowski, Neil Rabin, Merav Leiba, Albert Oriol, Ajai Chari, Jesús F. San Miguel, Paul G. Richardson, Saad Z. Usmani, Lisa O’Rourke, Kaida Wu, Tineke Casneuf, Christopher Chiu, Xiang Qin, Meletios A Dimopoulos
Nizar J. Bahlis, Philippe Moreau, Hareth Nahi, Torben Plesner, Hartmut Goldschmidt, Kenshi Suzuki, Robert Z. Orlowski, Neil Rabin, Merav Leiba, Albert Oriol, Ajai Chari, Jesús F. San Miguel, Paul G. Richardson, Sharjeel Usmani, Lisa O’Rourke, Kang Wu, Tineke Casneuf, Christopher Chiu, Xiang Qin, Meletios A Dimopoulos
Meletios A Dimopoulos, Albert Oriol, Hareth Nahi, Jesús F. San Miguel, NJ Bahlis, Neil Rabin, Robert Z. Orlowski, M. Komarnicki, Kazuyuki Suzuki, Trine Lindhardt Plesner
Meletios A Dimopoulos, Albert Oriol, Hareth Nahi, Jesús F. San Miguel, NJ Bahlis, Neil Rabin, Robert Z. Orlowski, M. Komarnicki, Kazuyuki Suzuki, Trine Lindhardt Plesner
Discussion(0)
No comments yet. Be the first to comment.